Bayer discontinues claims in labeling and marketing that linked selenium in its One A Day Men's multivitamins to reduced risk of prostate cancer, according to the Center for Science in the Public Interest. However, CSPI still may pursue the lawsuit it threatened the company with in June because "Bayer adamantly insists that its claims are perfectly legal and refuses to make any commitment not to start making them again," said Stephen Gardner, CSPI's director of litigation, in an Aug. 11 e-mail. A spokeswoman declined to comment on Bayer's future plans for selenium/prostate cancer claims, though the firm previously said it was halting use of the claims in light of new science and FDA's acceptance of extremely limited health claims for selenium (1"The Tan Sheet" July 6, 2009)
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
The US FTC’s contention that ‘notice and choice’ has failed as the cornerstone of consumer privacy regulation and must be abandoned in favor of data minimization and other more stringent measures does not adequately account for the complexity of business practices and consumer behavior, FTC commissioner Melissa Holyoak asserted at the NAD’s 2024 Annual Conference.
FTC Commissioner Melissa Holyoak says the agency has acted outside the bounds afforded by Congress, citing several areas within consumer protection, including a recent update to the final rule for the Health Breach Notification Rule and the commission’s use of notices of penalty offense to serve as the basis for Section 5 settlements.
At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
“We cannot ignore how Trump has taken a sledgehammer to the FDA ability to evaluate new drugs,” says California’s Nanette Diaz Barragán of California during Energy and Comme e markup discussion of five-year reauthorization of FDA’s OMUFA.
Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.
Decision to reformulate Mucinex sinus products without phenylephrine hits Reckitt's Q2 sales but the firm says it is preparing for upcoming cold & flu season with new marketing push.
